Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed diagnosis of 1 of the following:

- Non-small cell lung cancer (NSCLC), meeting 1 of the following criteria:

- Stage IIIB disease

- No pleural effusion and not a candidate for a combined modality
treatment

- Stage IV disease

- Local or metastatic failure after surgery and/or radiotherapy

- Colorectal cancer (CRC)

- Advanced and/or metastatic disease

- Suitable for first-line therapy with oxaliplatin, leucovorin calcium, and
fluorouracil (FOLFOX-6)

- Clinically or radiologically documented disease

- No tumor marker elevation as sole evidence of disease

- No necrotic/hemorrhagic metastases or tumor

- No untreated brain or meningeal metastases

- Previously treated, radiologic or clinical evidence of stable brain metastases
allowed provided disease is asymptomatic and corticosteroids are not required

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Hemoglobin normal

- Absolute granulocyte count ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance ≥ 50
mL/min

- Bilirubin ≤ 1.5 times ULN

- AST or ALT ≤ 2 times ULN (5 times ULN if liver involvement)

- Proteinuria ≤ grade 1

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No history of other malignancies except adequately treated nonmelanoma skin cancer or
other solid tumors curatively treated with no evidence of disease for ≥ 5 years

- No untreated and/or uncontrolled cardiovascular conditions or symptomatic cardiac
dysfunction

- No resting blood pressure (BP) consistently higher than systolic BP > 150 mm Hg and
diastolic BP > 100 mm Hg (in the presence or absence of a stable dose of
antihypertensive medication)

- No poorly controlled hypertension, history of labile hypertension, or poor compliance
with antihypertensive medication

- No overt bleeding (≥ 30 mL bleeding/episode) within the past 3 months

- No clinically relevant hemoptysis (≥ 5 mL fresh blood) within the past 4 weeks

- Flecks of blood in sputum allowed

- No active or uncontrolled infections

- No serious illnesses or medical conditions that would preclude compliance with study
requirements

- No mean QTc with Bazett's correction > 470 msec

- No history of familial long QT syndrome

- No peripheral neuropathy > grade 1

- No dihydropyrimidine dehydrogenase deficiency or history of severe hand-foot syndrome
after fluoropyrimidines (for patients with CRC)

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Recovered from prior therapy

- At least 6 months since prior adjuvant or neoadjuvant therapy

- At least 6 months since prior adjuvant radiotherapy

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin C)
(for patients with NSCLC)

- At least 4 weeks since prior and no concurrent corticosteroids

- At least 3 weeks since prior palliative radiotherapy and recovered

- Concurrent palliative radiotherapy allowed

- At least 2 weeks since prior epidermal growth factor receptor inhibitor therapy

- At least 2 weeks since prior major surgery

- No more than 1 prior single-agent, nonplatinum-containing chemotherapy regimen for
metastatic disease (for patients with NSCLC)

- No prior gemcitabine hydrochloride (for patients with NSCLC)

- No prior oxaliplatin (for patients with CRC)

- No prior angiogenesis inhibitor

- No prior chemotherapy for advanced/metastatic disease (for patients with CRC)

- No other concurrent experimental drugs or anticancer therapy